Drug Usage Trend study

Introduction to Drug Usage Trend study:

The "Usage Trend Study" looks in to various products' awareness, usage, satisfaction, product image and future usage expectations (increase/stay the same/decrease). This study was first started in 1984 as "Drug Usage and Satisfaction Study" via postal survey, and have been conducted over 40 times. In December 2006, the study was updated to the current methodology (online).

This study currently covers 10 therapeutic areas (drug types):

  1. Anti-hypertensive drugs
  2. Anti-hyperlipidemia drugs
  3. Antibiotics
  4. Anti-rheumatic arthritis drugs
  5. Oral chronic pain drugs
  6. Patch/tape non steroid anti-inflammatory drugs; NSAIDs
  7. Anti-allergy drugs (from Oct. 2007)
  8. BPH / urinary disorder treatment drugs (from Oct. 2007)
  9. Antidepressant drugs (from Nov. 2011)
  10. Alzheimer's disease drugs (from Nov. 2011)
    • *For the therapeutic type, studies were conducted as Oral NSAIDs until May 2013
    • For the above10 therapeutic types, past studies were conducted in following timing(s) of each year;
      Dec. 2006, Oct. 2007, every May & Nov. 2008~2011, every May since 2012
    • The latest study was conducted in May 2014

Outline of Drug usage trend study:

  1. Project name: Drug usage trend study
  2. Objective: To quantitatively understand the awareness, usage, product image, satisfaction and future usage intensions of various products.
  3. Methodology: Online survey (since Dec. 2006)
  4. Survey region: Nationwide
  5. Sample size: (differs depending on therapeutic area: see below for breakdown)

*Sample from latest version (May 2014 version for all)
 Hyper-
tension
Hyper-
lipidemia
AntibioticsOral chronic painPatch
NSAIDs
RAAllergyBPHAnti-
depressant
Alzheimer’s
disease
General IM244242265259260257260258190188
Gastroenterologists6157--------
Cardiologists6064--------
Endocrinologists5657--------
Nephrologists4240--------
Neurologists---------55
Pulmonologists--52---53---
Rheumatologists---343434----
Surgeons--104103103-----
Orthopedics---10199100----
Brain surgeons5554--------
Dermatologists--69---69---
ENT--69---69---
Urologists--111----112--
Pediatricians------71---
Psychiatrists--------167170
TOTAL (n=)518514670497496391522370357413

Contents of Drug usage trend study:

For each area, the study topics include:
  • Awareness and usage of specific drugs (see list below)
    • Allows you to see the product's share within the therapeutic area, and also the trend by looking at the past results.
    • Also it covers the reasons for using each product.
  • Product image
    • Each product is evaluated by various attributes (such as "strong efficacy" "long duration of effect" etc.) so that you can understand how products are positioned by the physicians.
  • Product satisfaction
    • Each product is evaluated numerically in terms of satisfaction levels (efficacy and safety).
  • Future usage expectations
    • Respondents are asked about their expected use of each product in 6 months time (increase, decrease, stay same, discontinue etc.).
    • For products they intend to switch (use less/discontinue), they are asked to which products they will switch to (including generics), and also the reason for why they intend to switch to that drug.

Product list for each area:
Anti-hypertensive drugs (May 2014 version)
  • Nu-Lotan (losartan): Banyu
  • Blopress (candesartan): Takeda
  • Diovan (valsartan): Novartis
  • Micardis (telmisartan): Boehringer Ingelheim/Astellas
  • Olmetec (olmesartan): Daiichi-Sankyo/Kowa
  • Irbetan (irbesartan): Shionogi
  • Avapro (irbesartan): Dainippon-Sumitomo
  • Azilva (azilsartan): Takeda
  • Preminent (losartan): Banyu
  • Co-DIO (valsartan/HCTZ): Novartis
  • Ecard (candesartan/HCTZ): Takeda
  • Micombi (telmisartan/HCTZ): Boehringer Ingelheim/Astellas
  • Irtra (irbesartan/HCTZ): Shionogi
  • Exforge (valsartan/amlodipine): Novartis
  • Rezaltas (olmesartan/azelnidipine): Daiichi-Sankyo
  • Unisia (candesartan/amlodipine): Takeda
  • Micamlo (telmisartan/amlodipine): Boehringer Ingelheim/Astellas
  • Aimix (irbesartan/amlodipine): Dainippon-Sumitomo/Shionogi
  • Atedio (valsartan/cilnidipine): Mochida
  • Zacras (azilsartan/amlodipine): Takeda
  • Norvasc (amlodipine): Pfizer
  • Amlodin (amlodipine): Dainippon-Sumitomo
  • Adalat CR (nifedipine): Bayer
  • Coniel (benidipine): Kyowa-Kirin
  • Atelec (cilnidipine): Mochida
  • Calblock (azelnidipine): Daiichi-Sankyo
  • Artist (carvedilol): Daiichi-Sankyo
  • Maintate (bisoprolol): Mitsubishi-Tanabe
  • Tenormin (atenolol): AstraZeneca/ Dainippon-Sumitomo
Anti-hyperlipidemia drugs (May 2014 version)
  • Mevalotin (pravastatin): Daiichi-Sankyo
  • Lipovas (simvastatin): Banyu
  • Lochol (fluvastatin): Novartis
  • Lipitor (atorvastatin): Astellas/Pfizer
  • Livalo (pitavastatin): Daiichi-Sankyo/Kowa
  • Crestor (rosuvastatin): AstraZeneca/Shionogi
  • Lipidil (fenofibrate): Takeda/Kaken/Asuka
  • Tricor (fenofibrate): Teijin
  • Bezatol SR (bezafibrate): Kissei
  • Cholebine (colestilan): Mitsubishi-Tanabe
  • Epadel (ethyl icosapentate): Mochida
  • Lotriga (omega-3-acid ethyl esters): Takeda
  • Zetia (ezetimibe): Schering-Plough
  • Caduet (amlodipine/atorvastatin calcium): Pfizer
Antibiotics (May 2014 version)
  • Flomox (cefcapene pivoxil): Shionogi
  • Cefzon (cefdinir): Astellas
  • Meiact (cefditoren): Meiji
  • Cravit250,500 (levofloxacin): Daiichi-Sankyo
  • Avelox (moxifloxacin): Bayer/Shionogi
  • Geninax (garenoxacin): Astellas/ Taisho-Toyama
  • Gracevit (STFX): Daiichi-Sankyo
  • Clarith (clarithromycin): Taisho-Toyama
  • Klaricid (clarithromycin): Abbott
  • Zithromac SR (azithromycin): Pfizer
  • Zithromac (except SR) (azithromycin): Pfizer
Anti-rheumatic arthritis drugs (May 2014 version)
  • Rheumatrex (methotrexate): Wyeth/Takeda
  • Rimatil (bucillamine): Santen
  • Azulfidine EN (sulfasalazine): Santen/Pfizer
  • Arava (leflunomide): Sanofi Aventis
  • Prograf (tacrolimus): Astellas
  • Careram (iguratimod): Eisai
  • Kolbet (iguratimod): Toyama-Kagaku
  • Zeljanz (tofacitinib citrate): Pfizer
  • Enbrel (etanercept): Wyeth/Takeda
  • Remicade (infliximab): Mitsubishi-Tanabe
  • Actemra (tocilizumab): Chugai
  • Humira (adalimumab): Abbott/Eisai
  • Orencia (abatacept): Bristol-Myers
  • Simponi (golimumab): Janssen/Mitsubishi-Tanabe
  • Cimzia (certolizumab pegol): UCB/Astellas
  • Methotrexate Tanabe (MTX): Mitsubishi-Tanabe
  • Methotrexate Sawai (MTX): Sawai
  • Metolate (MTX): Santen
Oral chronic pain drugs
(May 2014 version)
  • Voltaren (diclofenac): Novartis
  • Loxonin (loxoprofen): Daiichi-Sankyo
  • Osteluc (etodolac): Wyeth/Takeda
  • Hypen (etodolac): Nippon-Shinyaku
  • Lorcam (Lornoxicam): Taisho-Toyama
  • Mobic (meloxicam): Daiichi-Sanky
  • Celecox (celecoxib): Astellas/Pfizer
  • Tramal (tramadol hydrochloride): Nippon-Shinyaku/Pfizer
  • Tramcet (tramadol hydrochloride/acetaminophen): Mochida/Janssen
  • Lyrica (pregabalin) Pfizer/Eisai
Patch/tape non steroid anti-inflammatory drugs; NSAIDs (May 2014 version)
  • Mohrus PAP (ketoprofen): Hisamitsu
  • Miltax PAP (ketoprofen): Daiichi-Sankyo
  • Adofeed PAP (flurbiprofen): Kaken
  • Seltouch PAP (felbinac): Wyeth
  • Mohrus Tape (ketoprofen): Hisamitsu/Yutoku
  • Voltaren tape (diclofenac): Novartis
  • Loxonin PAP (loxoprofen): Daiichi-Sankyo
  • Loxonin tape (loxoprofen): Daiichi-Sankyo
  • Seltouch tape (felbinac): Teikoku/Takeda
  • Catlep tape (indometacin): Dainippon-Sumitomo
  • Voltaren gel (diclofenac): Novartis
  • Naboal gel (diclofenac): Hisamitsu
  • Napageln cream (felbinac): Pfizer
  • Idomethine (indometacin): Kowa
  • Loxonin gel (loxoprofen): Daiichi-Sankyo
Anti-allergy drugs
(May 2014 version)
  • Zaditen (ketotifen): Novartis
  • Alesion (epinastine): Boehringer-Ingelheim
  • Ebastel (ebastine): Dainippon-Sumitomo/Meiji
  • Zyrtec (cetirizine): Daiichi-Sankyo/GSK/UCB
  • Claritin (loratadine): Schering-Plough/Shionogi
  • Talion (bepotastine besilate): Mitsubishi-Tanabe
  • Allegra (fexofenadine): Sanofi
  • Dellegra (fexofenadine/pseudoephedrine): Sanofi
  • Allelock (olopatadine): Sanofi-Aventis
  • Xyzal (levocetirizine): GSK
  • Onon (pranlukast): Ono
  • Singulair (montelukast): Banyu
  • Kipres (montelukast): Kyorin
BPH / urinary disorder treatment drugs (May 2014 version)
  • Harnal (tamsulosin): Astellas
  • Flivas (naftopidil): Asahi-Kasei
  • Urief (silodosin): Kissei
  • Urief (silodosin): Daiichi-Sankyo
  • Ebrantil (urapidil): Kaken
  • Prostal L (chlormadinone): Aska
  • Perselin (allylestrenol): Schering-Plough
  • Eviprostat (eviprostat): Nippon-Shinyaku
  • Cernilton (cernitin pollen extract): Fuso
  • Avolve (dutasteride): GSK
  • Zalutia (tadalafil): Eli-Lilly/Nippon-Shinyaku
Antidepressants (May 2014 version)
  • Paxil (paroxetine): GSK/Dainippon-Sumitomo
  • Paxil CR (paroxetine): GSK/Dainippon-Sumitomo
  • Luvox (fluvoxamine maleate): Abbvie
  • Depromel (fluvoxamine maleate): Meiji Seika
  • Jzoloft (sertraline): Pfizer
  • Toledomin (milnacipran): Asahi-Kasei
  • Cymbalta (duloxetine): Shionogi
  • Reflex (mirtazapine): Meiji Seika
  • Remeron (mitrazapine): MSD
  • Lexapro (escitalopram oxalate): Mochida/Yoshitomi/Mitsubishi-Tanabe
  • Tricyclic antidepressant
  • Tetracyclic antidepressant
  • Abilify (aripiprazole): Otsuka
  • Zyprexa (olanzapine): Eli-Lily
  • Lamictal (lamotrigine): GSK
Drugs for Alzheimer’s disease (May 2014 version)
  • Aricept (donepezil): Eisai
  • Memary (memantine): Daiichi-Sankyo
  • Reminyl (galantamine): Janssen/Takeda
  • Exelon patch (rivastigmine): Novartis
  • Rivastach patch (rivastigmine): Ono
  • Yokukansan (traditional Chinese herbal medicine "yi-gan san")

Data sample (data below: actual data of 2008 BPH treatment drugs):

  • Results showed that majority of the physicians were prescribing Harnal (tamsulosin), to their BPH patients. Harnal (tamsulosin) also had the highest prescription rates, with 36.7% of BPH patients being prescribed with this.
Breakdown of Methodology

  • In the next 6 months, approximately half the respondents using Urief (silodosin) estimated that their usage of Urief will increase. Interesting to note, approximately half of the respondents using Avishot (naftopidil) mentioned that their usage will decrease or that they will discontinue using Avishot in the next 6 months. This is most likely due to fact that the announcement of Avishot discontinuing its sales was reported during the fieldwork duration. Majority of respondents mentioned that they will most likely switch to Flivas (naftopidil) in place of Avishot.
Breakdown of Methodology

PRICE:

Antihypertensive drugs = 750,000 YEN
All other disease topics = 500,000 YEN / per topic
  • *If payment is to be made domestically, additional 8% local tax will be added to the total fee